What Bio-Synthesis does

Bio-Synthesis Inc. is a privately held U.S.-based Contract Development and Manufacturing Organization (CDMO) founded in 1984 and headquartered at 800 Mario Court, Lewisville, Texas. The company specializes in custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, antisense oligonucleotides including steric-blocking ASOs, gapmer ASOs, and splice-switching oligonucleotides), peptides, and bioconjugates, serving biotechnology, pharmaceutical, diagnostic, and life science research organizations globally. Under CEO Miguel Castro, the firm operates with 11-50 employees and maintains ISO 9001:2015 and ISO 13485:2016 certifications, supporting workflows from research use through therapeutic development with GLP/GMP-aligned documentation.

The company's core technology platform integrates solid-phase oligonucleotide synthesis with an unusually broad modification chemistry portfolio, including phosphorothioate, 2'-OMe, 2'-MOE, 2'-F, LNA/BNA, cEt, PMO/PNA, TMO, PACE, and PN backbones, as well as chiral/stereopure configurations. Service lines are organized under the OligoTech at BSI and PeptideTech at BSI sub-brands, complemented by bioconjugation, molecular biology, analytical/QC, bioanalytical, immuno-chemistry, and formulation services including LNP encapsulation for RNA and protein delivery. Production capacity spans µmol screening lots through kilo-class manufacturing, with documented capability for batches up to 100 g in ASO development. The firm reports over 100,000 successful projects completed across 45+ years of operation.

Bio-Synthesis generates revenue on a project-based, quote-driven professional services model. Pricing is determined per project based on sequence complexity, chemistry platform, scale, purification requirements (HPLC, UPLC, PAGE), and QC documentation level, with no publicly listed tiered pricing. Distribution is direct: customers engage through online quote request forms, phone (800.227.0627), email ([email protected]), and consultative scientific engagement via the 'Speak to a Scientist' channel. Marketing is content-driven and educational, leveraging scientific calculators and a literature vault to attract biotech and pharma prospects. The firm is independently owned with no disclosed parent company, no identified venture capital backing, and no public listing.

Name

Bio-Synthesis

Legal name

Bio-Synthesis Inc

Website

https://biosyn.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

11–50 employees

Short description

Bio-Synthesis is a privately held U.S.-based custom synthesis CDMO founded in 1984, specializing in nucleic acids, peptides, and bioconjugates for biotechnology, pharmaceutical, diagnostic, and life science research organizations globally from its Lewisville, Texas facility.

Ownership category

akta.pro rank

Product category

Contract Manufacturing - Nucleic Acid Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Custom oligonucleotide synthesis
• Custom peptide synthesis
• Bioconjugation services
• Antisense oligonucleotide manufacturing
• CDMO chemistry services

Headquarters

HQ city

Seminole

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Custom Synthesis CDMO Services: Bio-Synthesis generates revenue through custom synthesis and chemistry development services for nucleic acids, peptides, and bioconjugates. Services span research scale through GMP manufacturing, with pricing based on sequence complexity, chemistry requirements, scale (from µmol screening lots through gram/kilo production), purification methods (HPLC, UPLC, PAGE), and QC documentation needs. The company supports RUO through GLP/GMP-aligned workflows with project-based pricing.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Bio-Synthesis operates as a Contract Development and Manufacturing Organization (CDMO) providing custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, ASOs, SSOs, gapmers), peptides, and bioconjugates from research scale through GMP manufacturing. The company supports pharmaceutical, biotechnology, diagnostic, and life science research organizations with advanced modification chemistries including PNA, PMO, LNA/BNA, NMA, and other specialty platforms.

Product overview

Bio-Synthesis operates as an integrated CDMO (Contract Development and Manufacturing Organization) platform offering custom synthesis, chemistry development, and therapeutic development support for nucleic acids, peptides, and bioconjugates. The core product portfolio centers on three main service platforms: OligoTech at BSI (encompassing oligonucleotide synthesis, ASO/SSO/Gapmer manufacturing, and specialty chemistry platforms including PNA, PMO, and advanced modified oligonucleotides), PeptideTech at BSI (providing custom peptide synthesis, peptide bioconjugation, and catalog peptides), and Bioconjugation Services (covering peptide-oligo conjugates, drug conjugates, and polymer conjugates). These are supported by Molecular Biology Services (cloning, gene synthesis, protein expression), Analytical & QC Services, Bioanalytical Services, Immuno Chemistry Services, and Formulation & Product Development including LNP encapsulation. The platform serves research through therapeutic development with scalable production capabilities and integrates scientific tools for oligonucleotide and peptide design.

Differentiator

Problem solved

Functional benefit

Brands

• OligoTech at BSI: Service platform for oligonucleotide synthesis services including custom DNA, RNA, oligonucleotides, siRNA, ASOs, modified oligos, probes, primers, and specialty nucleic acid constructs.
• PeptideTech at BSI

Products and services

• OligoTech at BSI Flagship custom oligonucleotide synthesis platform offering DNA, RNA, siRNA, ASO, SSO, and gapmer manufacturing with advanced modification chemistries for biotech, pharma, diagnostic, and research customers.
• PeptideTech at BSI Custom peptide synthesis service covering standard and modified peptides with analytical support, targeted at therapeutic, diagnostic, and research applications.
• Bioconjugation Services Custom bioconjugation services linking oligonucleotides, peptides, small molecules, dyes, and carriers to support targeted therapeutic and diagnostic conjugate development.
• Molecular Biology Services Supporting molecular biology offerings including cloning, mutagenesis, and gene synthesis for research and discovery-stage organizations.
• Analytical & QC Services Analytical and quality control services supporting custom synthesis programs, including LC-MS, HPLC, and release testing across research and GMP production batches.
• Formulation & Product Development Formulation, product development, and LNP encapsulation services supporting downstream therapeutic and diagnostic product development.
• Splice-Switching Oligonucleotide (SSO) Manufacturing Specialized manufacturing of splice-switching oligonucleotides, a distinct ASO modality for therapeutic splice modulation programs.
• Steric-Blocking ASO Synthesis Custom synthesis of steric-blocking antisense oligonucleotides for translational and preclinical therapeutic programs.
• Gapmer ASO Synthesis

Quantifiable outcome

• 45+ years of expertise supporting over 100,000 custom synthesis projects
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Agilent Technologies: Agilent offers custom oligonucleotide manufacturing through its Resolution Bioscience and genomics solutions, alongside its broader analytical instruments and life sciences portfolio. Larger incumbent serving overlapping customers in custom oligo and diagnostic probe markets.
• Thermo Fisher Scientific: Thermo Fisher provides custom oligonucleotide and peptide services through its Life Sciences Solutions segment, alongside a much broader CDMO and research products portfolio. A broad incumbent that competes for the same biotech and pharma CDMO customers as Bio-Synthesis at significantly greater scale.

Direct peers

• Bachem: Bachem is a leading peptide and oligonucleotide CDMO serving pharmaceutical and biotech customers worldwide, with deep specialization in GMP peptide API manufacturing. Comparable to Bio-Synthesis' PeptideTech platform and therapeutic-grade peptide offerings, with significantly larger commercial-scale capacity.
• Nitto Denko Avecia: Avecia (Nitto Denko Avecia) is a leading oligonucleotide CDMO providing process development, scale-up, and GMP manufacturing for therapeutic nucleic acids. Directly comparable to Bio-Synthesis' therapeutic oligo CDMO offering with substantially larger commercial-scale capacity.
• Biolegio: Biolegio is a specialized oligonucleotide CDMO providing custom DNA/RNA oligos, modified oligos, ASOs, siRNA, and GMP-grade nucleic acid manufacturing for therapeutic and diagnostic customers. Closely comparable specialty CDMO peer to Bio-Synthesis in Europe.
• GenScript: GenScript provides custom peptide synthesis, gene synthesis, protein expression, and oligonucleotide services through its CDMO and life-science research offerings. Overlaps directly with Bio-Synthesis' PeptideTech and Molecular Biology Services, and competes for biotech CDMO programs.
• Eurofins Genomics: Eurofins Genomics is a major custom oligonucleotide and gene synthesis service provider within the broader Eurofins Scientific network, serving research and diagnostic customers globally. Directly comparable to Bio-Synthesis across custom DNA/RNA oligo, primer, and probe synthesis.
• BioSpring: BioSpring is a specialized oligonucleotide CDMO focused on therapeutic nucleic acid manufacturing, including ASOs, siRNA, and mRNA. A close peer in therapeutic-grade oligo CDMO with comparable chemistry platforms, though operating at significantly larger scale (Frankfurt-based, multi-kg capacity).
• Integrated DNA Technologies (IDT): IDT is the largest custom oligonucleotide manufacturer globally (now part of Danaher), offering custom DNA/RNA oligos, ASOs, siRNA, and modified oligos to research, diagnostic, and therapeutic customers. Direct competitor to Bio-Synthesis' OligoTech at BSI across the full range of custom nucleic acid synthesis services.

Emerging players

• Cytiva (formerly Precision Nanosystems): Cytiva (via Precision Nanosystems acquisition) offers LNP encapsulation and mRNA formulation development services and instrumentation. Comparable to Bio-Synthesis' newly added LNP encapsulation service line for RNA/protein delivery formulations.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bio_synthesis
• Facebookfacebook.com/biosynthesisinc
• LinkedInlinkedin.com/company/bio-synthesis-inc.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Synthesis